Cytovation

Cytovation ASA is a clinical-stage biotechnology company based in Norway that focuses on precision medicine for patients with β-catenin driven tumors. Built on over 15 years of research from the University of Bergen and Haukeland University Hospital, the company has developed CY-101, a stable synthetic peptide that selectively targets cancer cell membranes while inhibiting the β-catenin pathway. With multiple completed Phase I trials and upcoming Phase II studies, Cytovation aims to expand immunotherapy benefits to a broader range of cancer patients.

Novel peptide engineering platform that develops stable synthetic peptides with dual mechanism targeting cancer cell membranes and β-catenin pathway inhibition to stimulate tumor-specific immune responses.

Total raised: $65M

Operating in the crowded immunotherapy space but differentiated through novel peptide-based dual mechanism approach. Competitors include established immunotherapy companies and checkpoint inhibitor developers, but unique targeting of β-catenin pathway provides potential competitive advantage in specific tumor types.